Medical News

RSS

KHN column: When bad news about health reform isn't bad

In his latest Kaiser Health News column, done in collaboration with The New Republic, Jonathan Cohn writes: "The weekend's newspapers included a pair of headlines about health care reform. And they were probably not the kind that reform advocates like to see" (7/19).

19 Jul 2010

Geron commences enrollment in imetelstat Phase 2 clinical trial for NSCLC

Geron Corporation today announced enrollment of the first patient in a randomized Phase 2 clinical trial of its telomerase inhibitor drug, imetelstat (GRN163L), as maintenance therapy following platinum-based induction therapy for patients with non-small cell lung cancer (NSCLC).

19 Jul 2010

Microarrays acquired from Vanderbilt University

Microarrays, Inc. (MI), an innovator of array-based technologies for biological research, detection and diagnostics, today announced that the company's management team and a group of independent investors have purchased MI from Vanderbilt University. The new company structure will allow MI to more quickly and nimbly respond to client's rapidly expanding needs, especially within the diagnostic and health care arenas.

19 Jul 2010

Biosystems International closes EUR2.1 million funding round

Biosystems International (BSI) SAS, Biotech Leader in the Development of Monoclonal Antibody Based Diagnostics for Cancer, Announced Today That it has Closed a Round of Funding Amounting to EUR2.1 Million ($2.7 Million).

19 Jul 2010

Erie County Medical Center to implement Allscripts EHR

Allscripts announced today that Erie County Medical Center Corporation, a 550-bed academic medical center in Buffalo, has selected the Allscripts Electronic Health Record (EHR) for 100 of its physicians to enhance the quality of patient care, improve physician and patient communications, and better manage the cost of care delivery in 24 outpatient clinics.

19 Jul 2010

TriLink, Affymetrix sign distribution and supply agreement

TriLink BioTechnologies, Inc. today announced that a multi-year distribution and supply agreement has been signed with California-based Affymetrix, Inc., a leading supplier of genetic analysis technologies. Under the terms of agreement, Affymetrix will use TriLink's high quality oligonucleotides in several of their kits.

19 Jul 2010

Mylan declares quarterly dividend of $16.25 per share

Mylan Inc. today announced that in accordance with its 2.139 million preferred stock issuance, the company has declared its quarterly dividend of $16.25 per share (based on the annual dividend rate of 6.5% and a liquidation preference of $1,000.00 per share) payable on Aug. 16, 2010, to holders of preferred stock of record as of Aug. 1, 2010.

19 Jul 2010

Encorium CRO acquires Progenitor

Encorium Group, Inc., a full service multinational clinical research organization (CRO) conducting studies in over 30 countries for many of the world's leading pharmaceutical and biotechnology companies, today announced that it has acquired Progenitor Holdings AG, a corporation organized in Switzerland and its wholly-owned subsidiaries organized in Mexico, Panama, Argentina, Chile, Switzerland, India and Hong Kong for cash and stock valued at EURO 1.7 million, plus earn-out consideration of cash and stock with a value of up to EURO 1.5 million.

19 Jul 2010

Authentidate completes sale $2.4M non-core assets to Star

Authentidate Holding Corp., a worldwide provider of secure Health Information Exchange, workflow management services and telehealth solutions, today announced that it has completed the previously announced sale of certain non-core assets to Star Advisors, LLC, acting on behalf of the principals of Astria Solutions Group, LLC, for approximately $2.4 million. The assets sold by the company include the company's land and building in Schenectady, NY, which was leased by Astria.

19 Jul 2010

Eisai's NDA for BANZEL Oral Suspension accepted for FDA review

Eisai Inc., a U.S. subsidiary of Eisai Co., Ltd. today announced that the U.S. Food and Drug Administration (FDA) has accepted for review Eisai's NDA for BANZEL® (rufinamide) Oral Suspension (40 mg/mL).

19 Jul 2010

EndoStim raises $6M in Series B equity financing round

EndoStim, Inc., a medical device company developing minimally-invasive interventional therapies to treat gastrointestinal and urological neuro-muscular disorders, today announced it has raised $6 million in Series B equity financing. Santé Ventures, a life science venture capital firm, led the round and was joined by the Prolog Ventures, Vectis Healthcare & Life Sciences Fund II and returning angel investors.

19 Jul 2010

FDA approves Mylan's ANDA for generic Catapres-TTS

Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.

19 Jul 2010

First Edition: July 19, 2010

Today's headlines include the latest news regarding the politics of implementing health reform as well as developments from the international AIDS conference now underway in Vienna.

19 Jul 2010

Phase 2 CUBICIN study for prosthetic joint infections meets primary endpoint

Cubist Pharmaceuticals, Inc., a leading acute care therapeutics company, today announced that its Phase 2 safety study of CUBICIN (daptomycin for injection) in the treatment of prosthetic joint infections caused by certain Gram positive pathogens met its study objectives. This study was a first-of-its-kind randomized controlled Phase 2 trial studying anti-infective therapy in the setting of 2-stage surgery for the replacement of infected prosthetic hip or knee joints.

19 Jul 2010

Researchers develop new method for producing image of individual DNA molecules' genetic make-up

A completely new method for producing an image of individual DNA molecules' genetic make-up has been developed by researchers in Sweden and Denmark. The results are published in the latest issue of the journal Proceedings of the National Academy of Sciences of the USA (PNAS).

19 Jul 2010

U.S. District Court upholds validity of Nycomed's Protonix patent

Nycomed announced today that Judge Jose L. Linares of the U.S. District Court for the District of New Jersey has confirmed the jury verdict in favor of Nycomed and Pfizer Inc. The decision upholds the jury verdict issued on April 23, 2010, confirming that the patent is valid and rejecting allegations by the defendants that the patent was invalid as obvious and invalid for double patenting. Against KUDCo, the US generic drug business of the Schwarz Pharma Group, which did not at-risk launch, final Judgment was entered as a result of Judge Jose L. Linares' rulings.

19 Jul 2010

Visage Imaging releases Amira 5.3 single platform brain imaging tool

Visage Imaging®, Inc., a wholly owned subsidiary of Pro Medicus Ltd., is pleased to announce the immediate release of Amira 5.3, a new major version of its market-leading software platform for visualizing, analyzing, and presenting complex 3D and 4D biomedical data.

19 Jul 2010

Novo Nordisk recruits 60,000th patient in world's largest observational study in insulin therapy

Today, Novo Nordisk announced the landmark recruitment of the 60,000th patient in the A1chieve(R) study - an observational study designed to investigate the effects of modern insulins in the management of type 2 diabetes.

From Novo Nordisk 19 Jul 2010

Phase II data on Genetic Immunity's DermaVir vaccine to be presented at XVIII International AIDS Conference

Genetic Immunity, a US/Hungarian biopharmaceutical company developing nanomedicine-based immunotherapies for HIV/AIDS and other chronic diseases, is releasing Phase II data on the Company's novel DermaVir therapeutic vaccine for HIV/AIDS during the XVIII International AIDS Conference this week in Vienna, Austria. DermaVir, the first dendritic cell-targeting topical HIV vaccine candidate, employs nanotechnology to induce multi-faceted and long-lived immune responses capable of eliminating HIV infected cells.

19 Jul 2010

ViroStatics to present VS411 Phase II dose-ranging trial data at International AIDS Conference in Vienna

ViroStatics, a US/Italian biopharmaceutical company developing innovative immunotherapies for HIV/AIDS and other chronic diseases, is releasing Phase II data from a randomized, dose-ranging trial of VS411, the Company's novel combination product for treating HIV/AIDS, during the XVII International AIDS Conference this week in Vienna, Austria.

19 Jul 2010